Utrophin

Utrophin is a protein that in humans is encoded by the UTRN gene. Utrophin is a large, cytoskeletal protein that is homologous to dystrophin, the protein mutated in patients with Duchenne Muscular Dystrophy (DMD). Due to its structural and functional similarities to dystrophin, utrophin has been studied extensively as a potential therapeutic target for DMD.

Structure

Utrophin is a member of the spectrin superfamily of proteins, which are known for their role in maintaining cell structure and integrity. It shares a similar domain structure with dystrophin, including a C-terminal domain that interacts with the dystroglycan complex, a central rod domain composed of spectrin-like repeats, and an N-terminal actin-binding domain. This structural similarity suggests that utrophin can compensate for the lack of dystrophin in muscle cells, potentially ameliorating the muscle weakness and degeneration seen in DMD.

Function

The primary function of utrophin is to stabilize the muscle cell membrane (sarcolemma) during muscle contraction and relaxation cycles. It achieves this by linking the actin cytoskeleton of muscle fibers to the extracellular matrix through the dystroglycan complex. This linkage is crucial for the integrity of muscle fibers and for the transmission of force generated within muscle cells to the bones, leading to movement.

Clinical Significance

Utrophin's similarity to dystrophin makes it a promising candidate for gene therapy and other therapeutic strategies in the treatment of DMD. Upregulation of utrophin expression in muscle cells has been proposed as a strategy to compensate for the lack of functional dystrophin in DMD patients. Several approaches, including pharmacological upregulation and gene therapy, are being explored to increase utrophin levels in dystrophic muscles.

Research and Development

Research into utrophin modulation as a therapeutic approach for DMD has led to the development of small molecules that can upregulate utrophin expression. These molecules aim to provide a functional substitute for dystrophin, thereby mitigating the progression of muscle degeneration in DMD patients. Clinical trials are ongoing to evaluate the efficacy and safety of these utrophin modulators.

See Also

• Dystrophin
• Muscular Dystrophy
• Gene Therapy
• Spectrin

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian